Clear Filters
Content type:
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Andrew Blauvelt, Curdin Conrad, Antonio Costanzo, et al.